<abbr id="skemw"><source id="skemw"></source></abbr>
<button id="skemw"><input id="skemw"></input></button>
<rt id="skemw"></rt>
<code id="skemw"><tr id="skemw"></tr></code>
<rt id="skemw"><acronym id="skemw"></acronym></rt>
<rt id="skemw"></rt>
您好!歡迎訪問廣州市超博科技有限公司的網站!
咨詢熱線: 18818844207
Bestatin (Synonyms:烏苯美司; Ubenimex)
Bestatin (Synonyms:烏苯美司; Ubenimex)
詳情說明 / Details
Bestatin (Synonyms:烏苯美司; Ubenimex)
目錄號 : KM12824 CAS No. : 58970-76-6 純度 : 98%
規格:

Bestatin (Ubenimex) 是 CD13 (Aminopeptidase N)/APN 和 leukotriene A4 hydrolase 抑制劑,常用于癌癥研究。

    生物活性

    Bestatin is a natural, broad-spectrum, and competitive CD13 (Aminopeptidase N)/APN and leukotriene A4 hydrolase inhibitor. Bestatin has anticancer effects.

    體外研究

    Bestatin enhances ATRA-induced differentiation and inhibits ATRA-driven phosphorylation of p38 MAPK in ATRA-sensitive APL NB4 cells. Bestatin can not reverse the differentiation block in ATRA-resistant APL MR2 cells. CD13 ligation with anti-CD13 antibody WM-15 results in phosphorylation of p38 MAPK, reduces the inhibition of Bestatin on the phosphorylation of p38 MAPK, and completely abolishes the enhancement of Bestatin on ATRA-inducing differentiation in NB4 cells. Bestatin (600 μM)-treated cells progress slower through the cell cycle due to decreased rate of cell growth and the frequency of cell division. Bestatin inhibits the frequency of mitosis and the inherent multinuclearity in D. discoideum, and is not cytotoxic to D. discoideum cells at 0-600 μM. Bestatin inhibits aminopeptidase activity in lysates of PsaA-GFP- and GFP-expressing cells by 69.39% and 39.93% of control, respectively.

    體內研究

    Bestatin (20 μM) significantly reduces CD13 expression in diabetic mice and results a significant inhibition of MMP-9 specific gelationolytic band densities compared to diabetic vehicle-treated mice. Bestatin treatment significantly inhibits the expression of VEGF and heparanase in diabetic mice. Intravitreal bestatin treatment significantly downregulates the expression of both HIF-1α and VEGF in diabetic mice retinas. Furthermore, the upregulated expression of heparanase in diabetic mice retinas is significantly inhibited by intravitreal bestatin treatment. Bestatin (10, 1, and 0.1mg/kg, i.p.) treatment before the antigen-potentiated humoral response to SRBC results in an increased number of splenocytes producing hemolytic anti-SRBC antibodies (PFC) and the 2-ME-resistant serum hemagglutinin titer (at a dose of 0.1 mg/kg). Bestatin (1 and 0.1 mg/kg) administered to mice five times on alternate days after cyclophosphamide injection does not change the suppressive effect of the drug regarding the number of PFC, and even causes the further decrease of the total anti-SRBC hemagglutinins at dose of 1 mg/kg on day 7 after antigen stimulation.

    分子式
    C16H24N2O4
    分子量
    308.37
    CAS號
    58970-76-6
    中文名稱
    烏苯美司
    運輸條件

    Room temperature in continental US; may vary elsewhere.

    儲存方式

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    溶解性數據
    In Vitro: 

    DMSO : 8.33 mg/mL (27.01 mM; Need ultrasonic)

    配制儲備液
    濃度溶劑體積質量 1 mg 5 mg 10 mg
    1 mM 3.2429 mL 16.2143 mL 32.4286 mL
    5 mM 0.6486 mL 3.2429 mL 6.4857 mL
    10 mM 0.3243 mL 1.6214 mL 3.2429 mL
    *

    請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產品失效。
    儲備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 儲存時,請在 6 個月內使用,-20°C 儲存時,請在 1 個月內使用。

    In Vivo:

    請根據您的實驗動物和給藥方式選擇適當的溶解方案。以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液,再依次添加助溶劑:

    ——為保證實驗結果的可靠性,澄清的儲備液可以根據儲存條件,適當保存;體內實驗的工作液,建議您現用現配,當天使用; 以下溶劑前顯示的百
    分比是指該溶劑在您配制終溶液中的體積占比;如在配制過程中出現沉淀、析出現象,可以通過加熱和/或超聲的方式助溶

    • 1.

      請依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 0.83 mg/mL (2.69 mM); Clear solution

      此方案可獲得 ≥ 0.83 mg/mL (2.69 mM,飽和度未知) 的澄清溶液。

      以 1 mL 工作液為例,取 100 μL 8.3 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中,混合均勻;向上述體系中加入50 μL Tween-80,混合均勻;然后繼續加入 450 μL生理鹽水定容至 1 mL。

    • 2.

      請依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 0.83 mg/mL (2.69 mM); Clear solution

      此方案可獲得 ≥ 0.83 mg/mL (2.69 mM,飽和度未知) 的澄清溶液。

      以 1 mL 工作液為例,取 100 μL 8.3 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中,混合均勻。

    • 3.

      請依序添加每種溶劑: 10% DMSO    90% corn oil

      Solubility: ≥ 0.83 mg/mL (2.69 mM); Clear solution

      此方案可獲得 ≥ 0.83 mg/mL (2.69 mM,飽和度未知) 的澄清溶液,此方案不適用于實驗周期在半個月以上的實驗。

      以 1 mL 工作液為例,取 100 μL 8.3 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中,混合均勻。

    臨床試驗
    科研文獻
    • ?J Med Chem. 2017 Mar 9;60(5):1817-1828.
    伊人久久大香线蕉av仙人| 久久99国产精一区二区三区| 亚洲午夜久久久精品影院| 亚洲国产精品无码久久青草| 久久婷婷国产综合精品| 久久九九久精品国产| 免费精品国产日韩热久久| 久久精品视频一区二区三区| 九九久久精品国产AV片国产| 久久综合久综合久久鬼色| 久久精品aⅴ无码中文字字幕| 国产福利电影一区二区三区久久久久成人精品综合 | 国产成人精品免费久久久久| 精品久久久久久中文| 亚洲国产精品综合久久2007| 久久免费视频网站| 久久99精品久久久久久不卡| 久久亚洲精品国产亚洲老地址| 久久精品人人爽人人爽快| 精品久久久久久国产免费了| 免费一本色道久久一区| 久久久久久久久久久久中文字幕| 亚洲中文字幕无码久久2017| 亚洲国产精品无码久久青草 | 久久青草免费91观看| 国产精品嫩草影院久久| 久久久久久久久久| 精品国产乱码久久久久软件 | 久久亚洲成a人片| 精品999久久久久久中文字幕| 国产99久久久国产精免费| 99久久综合精品五月天| 伊人无码精品久久一区二区| 人妻无码αv中文字幕久久| 久久精品人人做人人爽| 国内精品久久久久影院日本| 久久亚洲国产成人精品无码区| 天堂无码久久综合东京热| 色综合久久久无码中文字幕波多| 久久99这里只有精品国产| 久久国产真实乱对白|
  • <abbr id="a60w2"></abbr>
  • <strike id="a60w2"><input id="a60w2"></input></strike>